-
This Data Signals The End For Merck's Anacetrapib
Monday, April 4, 2016 - 11:33am | 281Read More...The ACCELERATE study data for Evacetrapib, which is a selective inhibitor of cholesteryl ester transfer protein [CETP] of Eli Lilly and Co (NYSE: LLY), was presented at the 2016 American College of Cardiology Conference. Leerink’s Seamus Fernandez mentioned that the data “clearly...
-
Fitbit Investors Take Profits Following Favorable Reaction To Blaze, Alta Shipment News
Friday, April 1, 2016 - 11:31am | 498Read More...The Fitbit Inc (NYSE: FIT) battle of bull versus bear continued on Friday as analysts at BlueFin Research Partners issued cautious commentary, while analysts at Leerink countered with a positive sentiment. Shares of Fitbit were higher by more than 1 percent on Friday, adding to the more than 25...
-
Data Shows Gilead's HCV Franchise Is Surviving New Competition
Monday, March 28, 2016 - 10:47am | 304Read More...Leerink’s Geoffrey C. Porges maintained an Outperform rating on Gilead Sciences, Inc. (NASDAQ: GILD), with a price target of $127. Porges mentioned that “current analysis of IMS script data and review of the largest payer plan formularies reveal that Gilead’s HCV DAAs are...
-
Novartis Shares Downgraded, Leerink Says 'Consensus Still Way Too High'
Wednesday, March 23, 2016 - 9:32am | 273Read More...Leerink’s Seamus Fernandez downgraded the rating for Novartis AG (ADR) (NYSE: NVS) from Outperform to Market Perform, while reducing the price target from $98 to $85. The analyst said that the consensus sales expectations for Entresto seemed unrealistic. Heart Failure [HF] guideline...
-
Leerink Raises Gilead Target To $130 On New HIV Outlook
Tuesday, March 8, 2016 - 10:52am | 249Read More...Leerink’s Geoffrey C. Porges maintained an Outperform rating for Gilead Sciences, Inc. (NASDAQ: GILD), while raising the price target from $125 to $130. The analyst said that the company’s new HIV franchise outlook reflected TAF adoption. Gilead Sciences dominates the market for two...
-
3 Mega Biotechs Leerink Loves
Monday, February 29, 2016 - 2:25pm | 357Read More...Leerink has released three new reports on some Outperform-rated big-name biotech stocks that the firm’s analysts like in coming months. Here’s a look at what the analysts had to say. Gilead Sciences, Inc. (NASDAQ: GILD) Analyst Geoffrey Porges has a positive view toward the stock,...
-
What Does The Street Think Of Fitbit Now?
Tuesday, February 23, 2016 - 6:23pm | 596Read More...Shares of Fitbit Inc (NYSE: FIT) have plunged more than 20 percent after the wearable device maker issued a weak outlook for the first quarter despite reporting better-than-expected earnings for the fourth quarter. Following the weak forecast, the stock faced a slew of downgrades from various...
-
Leerink Downgrades Orexigen, Cuts Target From $4.50 To $2
Tuesday, February 23, 2016 - 10:35am | 264Read More...Leerink’s Paul Matteis downgraded the rating for Orexigen Therapeutics, Inc. (NASDAQ: OREX) from Outperform to Market Perform, while reducing the price target from $4.50 to $2. Orexigen Therapeutics’s recent SEC filing provided details of the company’s Takeda agreement and...
-
Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug
Tuesday, February 16, 2016 - 2:47pm | 307Read More...According to a recent note out by Leerink, investor expectations toward one of Eli Lilly and Co (NYSE: LLY)'s drugs may need to be readjusted. During a biotech conference, panelists provided updates on Lilly's solanezumab, telling investors that the drug, while likely to be approved,...
-
Leerink Is Back On Board The Biotech Train
Friday, February 5, 2016 - 11:32am | 378Read More...Leerink has restarted coverage on eight large-cap biotech stocks following a prolonged period of share price underperformance. In a new report, analyst Geoffrey Porges explained why now is the time to buy back into biotech, but investors still must be selective. Porges pointed out that the selloff...
-
Does Oncomed Pharma Have Any Upside Left?
Tuesday, January 26, 2016 - 1:46pm | 256Read More...Oncomed Pharmaceuticals Inc (NASDAQ: OMED) shares are down 52 percent since July 27. Leerink’s Paul Matteis downgraded the rating for the company from Outperform to Market Perform, while reducing the price target from $27 to $11. Failure of Tarextumab raises questions regarding...
-
Leerink Boosts Intuitive Surgical Price Target To $640
Thursday, January 14, 2016 - 11:26am | 310Read More...Shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) have appreciated 18.94 percent over the past three months, reaching a high of $553.24 on January 6. Leerink’s Richard Newitter has maintained an Outperform rating on the company, while raising the price target from $600 to $640. The...
-
Eli Lilly's 2016 Guidance Released Next Week Could Disappoint, Leerink Warns
Monday, December 28, 2015 - 10:59am | 259Read More...Eli Lilly and Co (NYSE: LLY) shares have appreciated 24.44 percent year-to-date, from trading close to the 52-week low on December 31, 2014, at $68.99. Leerink’s Seamus Fernandez has maintained an Outperform rating on the company, while raising the price target from $93 to $95....
-
Leerink Highlights Biotechs Poised To Benefit From ASH Conference
Monday, November 30, 2015 - 2:13pm | 361Read More...On Monday, Leerink issued a report previewing the American Society of Hematology annual meeting, which will be held from December 5 to December 8. Leerink believes that this meeting will have meaningful clinical updates for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Juno Therapeutics Inc (...
-
UnitedHealth Could Ditch Obamacare: What It Means For Traders
Friday, November 20, 2015 - 3:34pm | 461Read More...Shares of UnitedHealth Group Inc (NYSE: UNH) have been volatile in 2015 and up 12 percent year-to-date. Cantor Fitzgerald’s Joseph D. France maintained a Hold rating on the company with a price target of $135, while Leerink’s Ana Gupta maintained an Outperform rating on the company,...
